Vertex beats Q4 expectations, shares rise on strong 2026 outlook
Biotech leader forecasts 8-9% revenue growth driven by gene therapy ramp and pain drug launch
Vertex Pharmaceuticals shares climbed in Thursday trading after the biotechnology company reported stronger-than-expected fourth-quarter results and issued bullish revenue guidance for 2026, signaling that its diversification beyond cystic fibrosis treatments is gaining momentum.
The Boston-based company delivered fourth-quarter earnings per share of $5.03, beating analyst estimates of $4.58 by 9.9%. Revenue of $3.19 billion exceeded expectations of $3.06 billion, representing a 4.3% upside to Wall Street forecasts.
More significantly, Vertex told investors to expect fiscal 2026 revenue between $12.95 billion and $13.1 billion, representing 8 to 9 percent growth compared to 2025 levels. The guidance includes expectations of more than $500 million in revenue from products outside its traditional cystic fibrosis franchise.
The company's diversification strategy is showing tangible results. CASGEVY, the groundbreaking CRISPR-based gene therapy for sickle cell disease and beta-thalassemia that Vertex co-developed with CRISPR Therapeutics, generated $116 million in revenue during 2025, surging 1,060 percent year-over-year. The therapy, which carries a list price of $2.2 million per patient, represents a new frontier for Vertex beyond its cystic fibrosis dominance.
JOURNAVX, Vertex's non-opioid pain treatment launched earlier this year, has quickly gained traction in the market with more than 550,000 prescriptions written. The oral therapy, approved for acute pain, represents Vertex's entry into the large pain management market, which has historically relied on opioids despite their addiction risks.
The company also highlighted the strong ramp of ALYFTREK, its next-generation cystic fibrosis treatment, though specific figures were not disclosed in the announcement. ALYFTREK is designed to address the approximately 10 percent of cystic fibrosis patients who cannot benefit from existing Vertex therapies.
Vertex's core cystic fibrosis franchise continues to underpin the company's financial performance. The company has dominated the cystic fibrosis treatment landscape for more than a decade, with medicines that address the underlying genetic cause of the disease rather than just symptoms. This dominant position has provided Vertex with the financial resources to invest in new therapeutic areas.
Analysts have maintained a largely positive outlook on the stock. With shares currently trading around $465, the consensus price target of $514.32 suggests room for upside, according to market data. Twenty-two analysts rate the stock a buy or strong buy, compared to six holding neutral ratings and two recommending sales.
The company's market valuation of approximately $120.7 billion reflects investor confidence in Vertex's pipeline beyond cystic fibrosis. The stock has gained roughly 28 percent over the past 12 months, outperforming broader biotechnology indices.
Looking ahead, investors will be watching the adoption trajectory of JOURNAVX in the competitive pain market, as well as the rollout of CASGEVY as manufacturing capacity and patient access expand. The gene therapy's commercial progress is particularly important given its transformative potential and the substantial investment required to bring CRISPR-based medicines to market.
Vertex's ability to successfully launch products in new therapeutic categories will determine whether it can maintain its premium valuation multiple. The company's price-to-earnings ratio of 33.11 times trailing earnings reflects high expectations for continued growth.
The company reported trailing twelve-month revenue of $11.7 billion with a profit margin of 31.4 percent, demonstrating strong operational efficiency alongside its research and development investments. This financial foundation provides Vertex with flexibility to pursue additional acquisitions and partnerships to supplement its internal pipeline.
For 2026, the midpoint of Vertex's revenue guidance at $13.03 billion would represent the company's first year crossing the $13 billion threshold, marking another milestone in its evolution from a cystic fibrosis specialist to a diversified biotechnology powerhouse.